Journal List > Tuberc Respir Dis > v.63(1) > 1001123

TOOLS
Kim: Sepsis
Review
Tuberculosis and Respiratory Diseases

Tuberculosis and Respiratory Diseases 2007; 63(1): 13-16.

Published online: 31 July 2007

DOI: https://doi.org/10.4046/trd.2007.63.1.13

Sepsis

Jae Yeol Kim, M.D.

Department of Internal Medicine, ChungAng University College of Medicine, Seoul, Korea.

Address for correspondence: Jae Yeol Kim, M.D. Department of Internal Medicine, ChungAng University Hospital 224-1 Heukseok-dong, Dongjak-gu, Seoul, 156-755, Korea. Phone: 82-2-6299-1396, Fax: 82-2-825-7571, jykimmd@cau.ac.kr

Copyright © 2007 The Korean Academy of Tuberculosis and Respiratory Diseases

Figures and Tables

Figure 1
Population-adjusted incidence of sepsis, according to sex, 1979??000. Martin et al, N Engl J Med 2003;348:1546.
trd-63-13-g001
Figure 2
Overall in-hospital mortality rate among patients hospitalized for sepsis, 1979-2000. Martin et al, N Engl J Med 2003;348:1546.
trd-63-13-g002
Table 1
Definition of systemic inflammatory response syndrome and sepsis
trd-63-13-i001

References

1. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000. 342:1301–1308.
2. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001. 345:1368–1377.
3. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definition for sepsis and organ failure and guidelines for the use of innovative therapies for the use of innovative therapies in sepsis. Chest. 1992. 101:1644–1655.
4. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001. 344:699–709.
5. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001. 345:1359–1367.
6. Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006. 354:449–461.
7. Bernard GR, Margolis BD, Shanies HM, Ely EW, Wheeler AP, Levy H, et al. Extended evaluation of recombinant human activated protein C United States trial (ENHANCE US): a single-arm,, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. Chest. 2004. 125:2206–2216.
8. The National Heart, Lung, and Blood Institute ARDS Clinical Trials Network. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med. 2001. 351:327–336.
9. Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, et al. Monocyte deactivation in septic patients: restoration by INF-gamma treatment. Nat Med. 1997. 3:678–681.
10. Hotchkiss RS, Chang KC, Swanson PE, Tinsley KW, Hui JJ, Klender P, et al. Caspase inhibitors improve survival in sepsis : a critical role of the lymphocyte. Nat Immunol. 2000. 1:496–501.
11. American College of Chest Physicians/Society of Critical Care Medicine. Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992. 20:864–874.
12. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003. 348:1546–1554.
13. Russell JA. Management of sepsis. N Engl J Med. 2006. 355:1699–1713.
14. Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. BMJ. 2004. 329:480.
TOOLS
Similar articles